Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials

MT newswire2026/09/01 08:51

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:51 AM EDT, 09/01/2026 (MT Newswires) -- Novartis (NVS) said Tuesday that phase 3 trials of remibrutinib showed significantly reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis. The trials met their primary endpoints and showed that remibrutinib was superior to teriflunomide on all key secondary measures. A preplanned combined analysis also showed a positive trend in three month confirmed disability progression and nominally significant results for six month confirmed disability progression, Novartis said. Remibrutinib also demonstrated a favorable safety profile with no liver safety signal, the company said. Novartis shares were over 4% higher in Tuesday premarket activity. Price: 158.47, Change: +6.41, Percent Change: +4.22

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.

华尔街见闻•2026/11/10 18:41